Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Wall Street saw slight gains on Thursday with positive earnings from major companies such as Eli Lilly and Tapestry. Despite ...

Wall Street was poised for a flat start as investors analyzed earnings from major companies like Honeywell and anticipated ...